ReviewCurrent treatment options in oncology2026
Recent Advances in Tumor-Infiltrating Lymphocyte Therapy for Melanoma.
Review in Current treatment options in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementMelanoma is the most aggressive form of skin cancer and remains a leading cause of skin cancer-related mortality. The therapeutic landscape of melanoma has been revolutionized by the advent of immune checkpoint inhibitors (ICIs), resulting in significant improvements in patient survival. Nevertheless, treatment-related toxicities, resistance mechanisms, and disease progression remain major barriers to durable clinical benefit, highlighting an ongoing unmet medical need. Tumor-infiltrating lymphocyte (TIL) therapy has emerged as a clinically active immunotherapeutic strategy for melanoma, particularly in patients with advanced or refractory disease. Continuous advances in biological understanding, manufacturing technologies, and clinical development have further strengthened its therapeutic potential. This review summarizes the biological basis of TIL therapy and outlines the manufacturing process from tumor procurement to lymphodepletion, TIL infusion, and interleukin-2 support. We then review current clinical evidence for conventional TIL products, including lifileucel, TM001, LM103, HS-IT101, and GC101, highlighting their efficacy and safety profiles. Emerging combination strategies integrating immune checkpoint inhibitors, targeted therapies, and oncolytic adenoviruses are also reviewed. In addition, advances in genetically engineered TILs, such as OBX-115, KSQ-001EX, and IOV-4001, are reviewed. Moreover, this review covers recent advances for improving therapeutic outcomes, including safety optimization, product optimization, next-generation engineered TILs, and predictive biomarkers. Challenges and future directions of TIL therapy in melanoma are also discussed. Overall, TIL therapy constitutes a rapidly evolving and clinically potent treatment modality for melanoma.
Indexed as
Identifiers
42726384What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.